Company: BIVIW
Filing Date: 2025-07-11
Form Type: S-1/A
Source: 0001520138-25-000205
Chunk: 57

Company: BIOVIE INC.
Filing Date: 2025-07-11
Form: S-1/A
Chunk 57
---
 pending patent applications that have been published can, subject to certain
limitations, be later amended in a manner that could cover our drug candidates or the use of our drug candidates. The scope of a patent
claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our
interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability
to market our drug candidates. We may incorrectly determine that our drug candidates are not covered by a third-party patent or may incorrectly
predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability
to develop and market our drug candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our
ability to develop and market our drug candidates.

In addition, if we fail to identify and correctly
interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle
or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be
significant, we may be temporarily or permanently prohibited from commercializing any of our drug candidates that are held to be infringing.
We might, if possible, also be forced to redesign drug candidates so that they no longer infringe the third-party intellectual property
rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources
that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results of operations
and prospects.

Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business.

Our commercial success depends upon our ability
to develop, manufacture, market and sell our drug candidates and use our proprietary technologies without infringing, misappropriating
or otherwise violating the intellectual property and other proprietary rights of third parties. There is considerable intellectual property
litigation in the pharmaceutical industry. We may become party to, or be threatened with, future adversarial proceedings or litigation
regarding intellectual property rights with respect to our drug candidates and their manufacture and our other technology, including reexamination,
interference, post-grant